Day One

Day One Biopharmaceuticals develops targeted therapies for pediatric and adult cancers, addressing significant unmet medical needs. It employs a distinct drug development approach, identifying and advancing promising oncology medicines. The pipeline emphasizes creating first-in-class or best-in-class solutions, aiming to overcome limitations in delivering specialized cancer care.

Co-founded in 2018 by Dr. Samuel Blackman and Julie Grant, Day One Biopharmaceuticals originated from a critical gap in oncology drug development. Founders observed traditional paradigms often neglected pediatric cancer patients, resulting in insufficient therapeutic options. Grant, from Canaan Partners, collaborated with Blackman to accelerate innovation for these underserved populations.

Day One Biopharmaceuticals primarily serves pediatric and adult patients battling various cancers where current treatments are inadequate. Its mission is to improve long-term outcomes for these individuals by advancing breakthrough therapies. The vision focuses on transforming cancer treatment, ensuring both children and adults receive urgently required targeted medicines.